Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 275 of 2051 entries
View as:

Lipid Efficacy/Tolerability Study (0524A-020)

Phase: N/A Priority: Normal
NCT ID: NCT00269204 Org: User:
Start: 12/31/05 End: 12/31/06 Due: 12/31/07

Study of the Effect of Diquafosol Tetrasodium Ophthalmic Solution, 2% Versus Placebo in Dry Eye Subjects (P08634)

Phase: N/A Priority: Normal
NCT ID: NCT00600288 Org: User:
Start: 01/31/08 End: 05/31/08 Due: 05/31/09

Comparison of the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616; Org 25969) in Elderly Participants With Adult Participants (MK-8616-029)

Phase: N/A Priority: Normal
NCT ID: NCT00474617 Org: User:
Start: 12/29/05 End: 10/20/06 Due: 10/20/07

Safety and Efficacy of Sugammadex (Org 25969, MK-8616) in Participants With or Having a Past History of Pulmonary Disease (19.4.308) (P05932) (MK-8616-017)

Phase: N/A Priority: Normal
NCT ID: NCT00475215 Org: User:
Start: 10/27/05 End: 09/09/06 Due: 09/09/07

Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00845065 Org: User:
Start: 02/28/09 End: 10/31/10 Due: 10/31/11

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

Phase: N/A Priority: Normal
NCT ID: NCT03711032 Org: User:
Start: 12/24/18 End: 11/20/34 Due: 11/20/35

Study of INS115644 Ophthalmic Solution in Subjects With Ocular Hypertension or Glaucoma

Phase: N/A Priority: Normal
NCT ID: NCT00443924 Org: User:
Start: 03/31/07 End: 04/30/09 Due: 04/30/10

Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)

Phase: N/A Priority: Normal
NCT ID: NCT00091559 Org: User:
Start: 02/03/05 End: 03/13/06 Due: 03/13/07

A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004)

Phase: N/A Priority: Normal
NCT ID: NCT00109109 Org: User:
Start: 12/01/03 End: 02/14/06 Due: 02/14/07

Use of Sugammadex Administered at 5 Minutes After Administration of 1.2 mg/kg Esmeron® (19.4.205)(P05942)

Phase: N/A Priority: Normal
NCT ID: NCT00379613 Org: User:
Start: 11/07/03 End: 07/14/04 Due: 07/14/05

Study To Estimate The Relative Bioavailability of Ertugliflozin (PF-04971729, MK-8835) in Healthy Adult Participants (MK-8835-039)

Phase: N/A Priority: Normal
NCT ID: NCT01114568 Org: User:
Start: 05/31/10 End: 06/30/10 Due: 06/30/11

Study of INS365 Ophthalmic Solution in Subjects With Dry Eye Disease

Phase: N/A Priority: Normal
NCT ID: NCT00404131 Org: User:
Start: 03/31/01 End: 12/31/01 Due: 12/31/02

Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)

Phase: N/A Priority: Normal
NCT ID: NCT02105454 Org: User:
Start: 05/23/14 End: 05/04/15 Due: 05/04/16

A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123)

Phase: N/A Priority: Normal
NCT ID: NCT01396005 Org: User:
Start: 09/30/11 End: 12/31/11 Due: 12/31/12

Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)

Phase: N/A Priority: Normal
NCT ID: NCT02332720 Org: User:
Start: 01/28/15 End: 05/03/17 Due: 05/03/18

European Safety Registry in Ulcerative Colitis (P04808)

Phase: N/A Priority: Normal
NCT ID: NCT00705484 Org: User:
Start: 06/01/07 End: 10/20/16 Due: 10/20/17

Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)

Phase: N/A Priority: Normal
NCT ID: NCT03302234 Org: User:
Start: 12/14/17 End: 09/07/22 Due: 09/07/23

A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors

Phase: N/A Priority: Normal
NCT ID: NCT00002235 Org: User:
Start: - End: - Due: -

A Study of MK-8527 in Healthy Adult Participants (MK-8527-013)

Phase: N/A Priority: Normal
NCT ID: NCT06826989 Org: User:
Start: 03/19/25 End: 06/04/25 Due: 06/04/26

Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)

Phase: N/A Priority: Normal
NCT ID: NCT00689390 Org: User:
Start: 02/20/07 End: 10/13/14 Due: 10/13/15

An Audit of Patients With Crohn's Disease Treated With Infliximab (P06066)

Phase: N/A Priority: Normal
NCT ID: NCT00988832 Org: User:
Start: 02/28/10 End: 12/31/10 Due: 12/31/11

ROTATEQ Reexamination Study (V260-037)

Phase: N/A Priority: Normal
NCT ID: NCT01074242 Org: User:
Start: 09/30/07 End: 06/30/13 Due: 06/30/14

A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)

Phase: N/A Priority: Normal
NCT ID: NCT00745823 Org: User:
Start: 09/30/08 End: 05/31/11 Due: 05/31/12

A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)

Phase: N/A Priority: Normal
NCT ID: NCT01767688 Org: User:
Start: 01/16/13 End: 03/07/13 Due: 03/07/14

A Study in Pediatric Patients With Cystic Fibrosis Lung Disease

Phase: N/A Priority: Normal
NCT ID: NCT00130182 Org: User:
Start: 08/31/05 End: - Due: -